Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

Human Vaccines

Volumn 6, Issue 11, 2010, Pages 888-893

  Ikematsu, Hideyuki ^a   Nagai, Hideaki ^b   Kawashima, Masahiro ^b   Kawakami, Yasunobu ^a   Tenjinbaru, Kazuyoshi ^c   Maeda, Atsushi ^c   Li, Ping ^d   Gillard, Paul ^e   Roman, François ^e  

^a Hara Doi Hospital   (Japan)

^b TOKYO NATIONAL HOSPITAL   (Japan)

^c Development and Medical Affairs Division   (Japan)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; Adults; AS03; H1N1; Immunogenicity; Influenza; Japan; Pandemic

Indexed keywords

INFLUENZA A H1N1 VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL; SEROCONVERSION; SHIVERING;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, SUBUNIT;

EID: 78649385920     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.11.12851     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention; Update: swine influenza A (H1N1) infections - California and Texas. MMWR Morb Mortal Wkly Rep 2009; 58:435-7.
2. Centers for Disease Control and Prevention; Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico. MMWR Morb Mortal Wkly Rep 2009; 58:467-0.
3. Centers for Disease Control and Prevention; CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States 2009. Available: http://www.cdc.gov/h1n1flu/estimates-2009-h1n1.htm. Accessed 2010.
4. Weekly Epidemiological Record (WER); No. 25 2009; 84:249-60. Available: http://www.who.int/wer/2009/wer8425.pdf. Accessed 2010.
5. World Health Organization. Pandemic (H1N1) 2009 - update 103. June 4, 2010. Global Alert and Response (GAR). Available: http://www.who.int/csr/don/ 2010-06-04/en/. Accessed 2010.
6. Interim planning considerations for mass gatherings in the context of pandemic (H1N1) 2009 influenza. WHO Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521-4.
7. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-2.
8. Dawood FS, Jain S, Finelli L, Shaw MW, Shaw MW, Lindstrom S, et al. [Virus Investigation Team]. Novel Swine-Origin Influenza A (H1N1). Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15. Erratum in: N Engl J Med 2009; 361:102.
9. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an Inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
10. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1345-51.
11. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5. (Pubitemid 40503646)
12. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
13. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90.
14. Ministry of Health, Labour and Welfare; Influenza sentinel surveillance report (4 December 2009). Ministry of Health, Labour and Welfare. Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2009/12/dl/infuh1204-05. pdf. Accessed 2010. Japanese.
15. Ministry of Health, Labour and Welfare; Influenza sentinel surveillance report (January 2010). Ministry of Health, Labour and Welfare. Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2010/02/dl/infuh0205-05. pdf. Accessed 2010. Japanese
16. Kamigaki T, Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr Influenza 2009; 1139. Available: http://knol.google.com/k/taro-kamigaki/epidemiological- characteristics-and-low/38epug6fmizmk/1#. Accessed 2010.
17. Ministry of Health, Labour and Welfare; Pandemic (H1N1) surveillance report of hospitalized cases (2 December 2009). Ministry of Health, Labour and Welfare. Available: http://www.mhlw.go.jp/kinkyu/kenkou/influenza/houdou/2009/ 12/dl/infuh1202-01.pdf. Accessed 2010. Japanese
18. Centers for Disease Control and Prevention (CDC) Document2. Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States 2010. Available: http://www.cdc.gov/h1n1flu/estimates-2009-h1n1.htm. Accessed 2010.
19. Use of Influenza A (H1N1) 2009 Monovalent Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2009. MMWR 2009; 58:1-8.
20. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
21. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
22. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Martine Denis. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8.
23. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:55-66.
24. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49-55.
25. Saitoh A, Nagai A, Tsuchida T, Sako M, Maekawa T, Yahagi N, et al. Immunogenicity and safety of an AS03-adjuvanted A/H1N1v pandemic influenza vaccine in Japanese children aged 6 months to 17 years: a preliminary report. Presented at the International Symposium on Respiratory Viral Infections 2010.
26. B-adjuvanted H1N1 2009 vaccine in children 6-35 months - Preliminary report. Presented at the International Symposium on Respiratory Viral Infections 2010.
27. A adjuvant. Presented at the International Symposium on Respiratory Viral Infections 2010.
28. A. adjuvant: Preliminary report of an observer-blind, randomized controlled trial. Vaccine 2010; 28:1740-5.
29. A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open nonrandomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57.
30. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A. Available: http://www.who.int/csr/resources/publications/swineflu/candidates-X- 179a/en/. Accessed 2009.
31. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, Van Hoeke C. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69.
32. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/ 2006). European Agency for the Evaluation of Medicinal Products 2007.
33. FDA Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available: http://www.fda.gov/cber/gdlns/panfluvac.htm. Accessed 2010.